---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-023068"
form_type: "8-K"
ticker: "ATXI"
cik: "0001644963"
company_name: "AVENUE THERAPEUTICS, INC."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T17:51:45.290991+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Avenue Therapeutics Q2 net loss $4.0M; first AJ201 patient dosed, FDA agrees on tramadol Phase 3 design

## Summary
- Net loss of $4.0M ($0.52 per share) vs $0.6M ($0.41) in Q2 2022; cash $1.6M down from $6.7M at year-end 2022.
- First patient dosed in Phase 1b/2a trial of AJ201 for SBMA; topline data expected H1 2024.
- BAER-101 preclinical results show full seizure suppression at 0.3 mg/kg in GAERS model; Phase 2a planned for 2024.
- FDA alignment on Phase 3 safety study design for IV tramadol; subject to financing, company aims to start soon.
- R&D expense surged to $3.0M from $0.2M; G&A $0.9M vs $0.5M, reflecting clinical progress.

## SEC filing metadata
- accession: 0001437749-23-023068
- form_type: 8-K
- ticker: ATXI
- cik: 0001644963
- company_name: AVENUE THERAPEUTICS, INC.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1644963/000143774923023068/0001437749-23-023068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1644963/000143774923023068/atxi20230530_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-023068
- JSON: https://secwatch.observer/filing/0001437749-23-023068.json
- Plain text: https://secwatch.observer/filing/0001437749-23-023068.txt

## Key facts
- Earnings Releases
  AVENUE THERAPEUTICS, INC. reported second quarter ended June 30, 2023 results: net income Net loss attributable to common stockholders for the second quarter of 2023 was $4.0 million, or $0.52 per share, EPS $0.52 per share.
  - Period: second quarter ended June 30, 2023
  - Net income: Net loss attributable to common stockholders for the second quarter of 2023 was $4.0 million, or $0.52 per share
  - EPS: $0.52 per share
  - Result: reported results
  source text: On August 10, 2023, Avenue Therapeutics, Inc. (the “Company” or “Avenue”) issued a press release to provide a corporate update and to announce its financial results for the three months ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1644963/000143774923023068/0001437749-23-023068-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.